Arsenic trioxide

Generic Name: Arsenic trioxide

Brand Names: Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac

Drug Type: Small Molecule

Chemical Formula: As_₂O_₃

CAS Number: 1327-53-3

Unique Ingredient Identifier: S7V92P67HO

Background: Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredo...

Indication: For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression

Associated Conditions: Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia

Associated Therapies: -

Clinical Trials

Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-09-19

Last Posted Date: 2009-01-23

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 40

Registration Number: NCT00193544

Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain Cancer

First Posted Date: 2005-09-16

Last Posted Date: 2009-04-09

Lead Sponsor: Stanford University

Target Recruit Count: 12

Registration Number: NCT00185861

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Liver Cancer

First Posted Date: 2005-08-10

Last Posted Date: 2017-04-27

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 25

Registration Number: NCT00128596

Locations: 🇺🇸
UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States

Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: pamidronate disodium
Drug: arsenic trioxide
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2005-07-28

Last Posted Date: 2013-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00124605

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase 2

Terminated

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2005-07-11

Last Posted Date: 2018-05-11

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 1

Registration Number: NCT00118196

Locations: 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Phase 2

Withdrawn

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Refractory Plasma Cell Neoplasm

First Posted Date: 2005-06-03

Last Posted Date: 2013-07-10

Lead Sponsor: The Cleveland Clinic

Registration Number: NCT00112879

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Phase 2

Terminated

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2005-03-04

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 5

Registration Number: NCT00104806

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-11-09

Last Posted Date: 2011-04-22

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 36

Registration Number: NCT00095771

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Leukemia

First Posted Date: 2004-10-08

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00093366

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-10-08

Last Posted Date: 2014-01-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 61

Registration Number: NCT00093483

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy